Skip to main content
Premium Trial:

Request an Annual Quote

Camena Bioscience Closes $10M Series A Financing Round

NEW YORK – UK synthetic biology startup Camena Bioscience said on Monday that it has closed a $10 million Series A financing round that was led by venture capital firm Mercia.

Cambridge-based Camena said it will use the money to scale its operations and to further develop its gSynth enzymatic DNA synthesis platform, which it claimed can produce DNA of over 300 bp length with 90 percent accuracy.

The firm said it has already signed commercial agreements "with leading consumers of synthetic genes, securing a multimillion-pound revenue stream over the previous year."

Camena is joining a number of other companies that are also betting on enzymatic DNA synthesis, including DNA Script, Ansa Biotechnologies, Molecular Assemblies, Twist Bioscience, Evonetix, and NunaBio.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.